Why the study?
CKD in T2D increases the risk of ESRD and CVD, but recommended routine UACR testing is currently performed in only a minority of patients.
Routine UACR testing is critical for early detection of CKD in patients with type 2 diabetes, but significant barriers to its implementation remain in community clinical settings.
Answers are grounded in this paper and cite their sources.
Barriers to UACR testing persist in community settings; leaves open optimal implementation strategies for type 2 diabetes.
Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is associated with increased risk of end-stage renal disease (ESRD) and cardiovascular disease (CVD). Urine albumin-to-creatinine ratio (UACR) is a sensitive and early indicator of kidney damage, which should be used routinely to accurately assess CKD stage and monitor kidney health. However, this test currently is performed in only a minority of patients with T2D. Here, we review the importance of albuminuria testing and current barriers that hinder patient access to UACR testing and describe solutions to such testing in a community clinical setting.
No takes yet. Share an insight, caveat, or question.
Christofides et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: